128 related articles for article (PubMed ID: 38917592)
1. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence.
Lyu SI; Fretter C; Simon AG; Spielmann SM; Damanakis AI; Zhao Y; Bruns CJ; Schmidt T; Popp FC; Waldschmidt D; Quaas A; Knipper K;
Transl Oncol; 2024 Jun; 47():102044. PubMed ID: 38917592
[TBL] [Abstract][Full Text] [Related]
2. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
3. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
4. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression.
Park S; Shin K; Kim IH; Hong T; Kim Y; Suh J; Lee M
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629433
[TBL] [Abstract][Full Text] [Related]
6. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
7. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
[TBL] [Abstract][Full Text] [Related]
8. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
9. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
[TBL] [Abstract][Full Text] [Related]
11. Characterization of zolbetuximab in pancreatic cancer models.
Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
[TBL] [Abstract][Full Text] [Related]
12. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
13. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer.
Zeng Y; Lockhart AC; Jin RU
Expert Opin Drug Discov; 2024 Jun; ():1-14. PubMed ID: 38919123
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.
Liang Z; Liu L; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Front Oncol; 2023; 13():1258347. PubMed ID: 37886169
[TBL] [Abstract][Full Text] [Related]
15. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
16. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Cutsem EV; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
Future Oncol; 2024 May; ():1-17. PubMed ID: 38861294
[TBL] [Abstract][Full Text] [Related]
17. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes.
Kayikcioglu E; Yüceer RO
Medicine (Baltimore); 2023 Feb; 102(6):e32882. PubMed ID: 36820561
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
19. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
[TBL] [Abstract][Full Text] [Related]
20. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies.
Grizzi G; Venetis K; Denaro N; Bonomi M; Celotti A; Pagkali A; Hahne JC; Tomasello G; Petrelli F; Fusco N; Ghidini M
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
